相关实验视频

Updated: Feb 24, 2026

A Standard Methodology to Examine On-site Mutagenicity As a Function of Point Mutation Repair Catalyzed by CRISPR/Cas9 and SsODN in Human Cells

A Standard Methodology to Examine On-site Mutagenicity As a Function of Point Mutation Repair Catalyzed by CRISPR/Cas9 and SsODN in Human Cells

Published on: August 25, 2017

增强CRISPR/Cas介导基因淘汰,使用短非同源的寡核酸

Yen Peng Chew¹, Aron Ferenczi¹, Marie Dannay¹

¹Institute of Molecular Plant Sciences, University of Edinburgh, Edinburgh, UK.

Plant biotechnology journal

|February 23, 2026

概括

研究人员在绿藻Chlamydomonas reinhardtii中提高了基因淘汰效率,高达100倍,使用CRISPR-Cas编辑与短双链非同类寡度氧核化物 (dsNHOs). 这种非同源性寡核酸增强 (NOE) 策略改善了合成生物学应用.

科学领域:

合成生物学合成生物学
分子生物学分子生物学
藻类生物技术藻类生物技术

背景情况:

Chlamydomonas reinhardtii是一种模范绿藻,在生产重组蛋白质和化学品方面具有重要的工业潜力.
克里斯普尔-卡斯技术能够在C. reinhardtii中进行基因组编辑,但低基因淘汰 (KO) 效率限制了其在通路工程和功能基因组学中的应用.

研究的目的:

为了提高克里斯普尔-卡斯介导基因淘汰在克拉米多莫纳斯 reinhardtii的疗效.
研究增强基因淘汰效率的机制和影响因素.

主要方法:

同时提供CRISPR-Cas试剂与短双链非同类寡度氧核化物 (dsNHOs).
对 dsNHO 的长度,结构和化学变化的分析.
研究KU70/80 (KU) 异构体在增强过程中的作用.
评估不同基因位置和菌株的基因淘汰疗效.

主要成果:

同时提供dsnhos可将基因淘汰疗效提高100倍.
这种增强,称为非同类寡核酸增强 (NOE),取决于dSNHO特征.
NOE通过KU70/80异构体以独立于Cas核酶,位点或菌株的方式进行介导.
dsNHOs似乎破坏了DNA双链断裂感知通路,有利于微同质介导末端连接 (MMEJ) 而不是正规非同质末端连接 (c-NHEJ).

结论:

非同源性寡核酸增强 (NOE) 是一种强有力的策略,可显著提高克里斯普尔-卡斯介导基因淘汰效率.
这种方法为推进合成生物学和功能基因组研究在这种模型藻类中提供了有价值的工具.
这些发现表明NOE在其他生物体中的潜在应用,以提高基因编辑结果.

关键词:

这就是CRISPR/CasPR.克拉米多莫纳斯病毒是什么?KU70/80 异构聚物异构聚物基因淘汰赛基因淘汰赛非同类的寡核酸增强剂

更多相关视频

Removal of an Internal Translational Start Site from mRNA While Retaining Expression of the Full-Length Protein

Removal of an Internal Translational Start Site from mRNA While Retaining Expression of the Full-Length Protein

Published on: March 16, 2022

Selection-dependent and Independent Generation of CRISPR/Cas9-mediated Gene Knockouts in Mammalian Cells

Selection-dependent and Independent Generation of CRISPR/Cas9-mediated Gene Knockouts in Mammalian Cells

Published on: June 16, 2017

相关概念视频

Homologous Recombination

Homologous Recombination

The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...

CRISPR/Cas9 Genome Editing

CRISPR/Cas9 Genome Editing

The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...

CRISPR

CRISPR

Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...